|1.||Wei, Qun: 5 articles (11/2012 - 09/2007)|
|2.||Shlapobersky, Mark: 4 articles (11/2012 - 10/2009)|
|3.||Rolland, Alain: 4 articles (11/2012 - 08/2007)|
|4.||Rusalov, Denis: 4 articles (11/2012 - 08/2007)|
|5.||Smith, Larry R: 3 articles (12/2015 - 09/2007)|
|6.||Sullivan, Sean: 3 articles (11/2012 - 10/2009)|
|7.||Ferrari, Marilyn: 3 articles (01/2012 - 03/2006)|
|8.||Kaslow, David C: 3 articles (09/2007 - 03/2006)|
|9.||Hartikka, Jukka: 2 articles (12/2015 - 11/2012)|
|10.||Sullivan, Sean M: 2 articles (10/2013 - 11/2012)|
01/01/2014 - "The chemokine, MIP3αCCL20, did not significantly enhance the cellular infiltrate or levels of cytokine or chemokine expression at the immunization site but acted with Vaxfectin to reduce liver stage malaria infection by orders of magnitude compared to vaccine constructs lacking the chemokine component. "
04/09/2010 - "We previously reported the capacity of the cationic lipid-based formulation, Vaxfectin, to enhance the immunogenicity and protective efficacy of a low dose plasmid DNA vaccine against Plasmodium yoelii malaria in mice. "
03/10/2006 - "We evaluated the capacity of the cationic lipid based formulation, Vaxfectin, to enhance the immunogenicity and protective efficacy of DNA-based vaccine regimens in the Plasmodium yoelii murine malaria model. "
04/09/2010 - "These data showing that Vaxfectin can enhance the immunogenicity of plasmid DNA vaccines administered at low doses per body weight, and in combinations, has important clinical implications for the development of a vaccine against malaria, as well as against other public health threats."
01/01/2014 - "By using a novel, lipid-based adjuvant, Vaxfectin, to attract immune cells to the immunization site, in combination with an antigen-chemokine DNA construct designed to target antigen to immature dendritic cells, we elicited a humoral immune response that provided sterilizing immunity to malaria challenge in a mouse model system. "
|2.||Herpes Genitalis (Genital Herpes)
11/19/2012 - "A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes."
06/01/2012 - "Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection."
11/19/2012 - "Here we describe studies in the guinea pig model of genital herpes to evaluate a novel plasmid DNA (pDNA) vaccine encoding the HSV-2 glycoprotein D and UL46 and UL47 genes encoding tegument proteins VP11/12 and VP 13/14 (gD2/UL46/UL47), formulated with a cationic lipid-based adjuvant Vaxfectin(®). "
|3.||Dengue (Dengue Fever)
01/05/2012 - "Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine."
01/05/2012 - "We conducted a nonhuman primate study to evaluate the effect of Vaxfectin(®) on the immunogenicity of a tetravalent dengue DNA vaccine. "
01/05/2012 - "These results support further evaluation of the Vaxfectin(®)-adjuvanted tetravalent dengue DNA vaccine in a Phase 1 clinical trial."
01/05/2012 - "Animals were immunized on days 0, 28 and 84, with each immunization consisting of 3mg of Vaxfectin(®)-adjuvanted tetravalent dengue DNA vaccine. "
01/05/2012 - "The use of Vaxfectin(®) resulted in a significant increase in anti-dengue neutralizing antibody responses against dengue-1, -3 and -4. There was little to no effect on T cell responses as measured by interferon gamma ELISPOT assay. "
01/05/2012 - "Animals immunized with the Vaxfectin(®)-formulated tetravalent DNA vaccine showed significant protection against live dengue-2 virus challenge compared to control animals (0.75 mean days of viremia vs 3.3 days). "
10/01/2013 - "Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia."
11/19/2012 - "Prophylactic immunization with Vaxfectin(®)-gD2/UL46/UL47 significantly reduced viral replication in the genital tract, provided complete protection against both primary and recurrent genital skin disease following intravaginal HSV-2 challenge, and significantly reduced latent HSV-2 DNA in the dorsal root ganglia compared to controls. "
|1.||DNA (Deoxyribonucleic Acid)
|2.||Proteins (Proteins, Gene)
|3.||glycoprotein D-herpes simplex virus type 2
|7.||Human Growth Hormone (Saizen)
|10.||Interferon-gamma (Interferon, gamma)